RNA-Lipid Technology for Novel Applications

Publication ID: 24-11857681_0007_PTD
Published: October 28, 2025
Category:New Applications & Use Cases

Legal Citation

pr1or.art Inc., “RNA-Lipid Technology for Novel Applications,” Published Technical Disclosure No. 24-11857681_0007_PTD, Published October 28, 2025, available at https://archive.pr1or.art/24-11857681_0007_PTD
This technical disclosure describes improvements that would be readily apparent to a Person Having Ordinary Skill In The Art (PHOSITA) when considered in combination with the foundational architecture disclosed in U.S. Patent No. 11,857,681.

Summary of the Inventive Concept

This inventive concept leverages RNA-lipid technology to address pressing problems in personalized nutrition, food waste reduction, air quality monitoring, sustainable agriculture, and bioremediation, demonstrating the versatility of this core technology in new industries and use cases.

Background and Problem Solved

The original patent focused on non-viral delivery of RNA for immunization. However, the limitations of this approach lie in its restricted application to the field of immunization. This inventive concept solves the problem of limited scope by applying the RNA-lipid technology to entirely new fields, tackling critical issues in various industries.

Detailed Description of the Inventive Concept

The inventive concept comprises RNA molecules encoding specific guidance, indicators, sensors, enhancers, or enzymes, which are then delivered using lipid particles tailored for each application. For personalized nutrition, RNA molecules are synthesized based on a user's genetic profile and dietary needs. In food waste reduction, RNA molecules encode spoilage indicators, and lipid-based sensors detect spoilage. For air quality monitoring, RNA molecules encode air quality sensors, and lipid particles enhance detection sensitivity. In sustainable agriculture, RNA molecules encode crop yield enhancers, and lipid particles target plant roots. Finally, in bioremediation, RNA molecules encode pollution-degrading enzymes, and lipid-based sensors detect degradation.

Novelty and Inventive Step

The novelty of this inventive concept lies in the unexpected application of RNA-lipid technology to new industries and use cases, which is non-obvious compared to the original patent's focus on immunization. The inventive step involves the design and synthesis of RNA molecules and lipid particles tailored for each specific application, demonstrating a significant departure from the original patent's scope.

Alternative Embodiments and Variations

Alternative embodiments include using different types of lipid particles, modifying the RNA molecules to target specific cell types, or integrating the RNA-lipid technology with other sensing or detection methods. Variations could include applying the technology to other industries, such as cosmetics or pharmaceuticals, or developing new RNA-lipid formulations for specific applications.

Potential Commercial Applications and Market

This inventive concept has significant commercial potential in various industries, including personalized health and wellness, food technology, environmental monitoring, sustainable agriculture, and bioremediation. The market for these applications is vast, with potential customers ranging from individual consumers to large corporations and government agencies.

CPC Classifications

SectionClassGroup
A A61 A61K9/127
A A61 A61K9/1272
A A61 A61K31/7088
A A61 A61K39/00
A A61 A61K39/12
C C12 C12N15/86
A A61 A61K39/39
A A61 A61K2039/53
A A61 A61K2039/55555
C C12 C12N2710/16134
C C12 C12N2760/18534
C C12 C12N2770/36134

Field of Art

Biotechnology and pharmaceutical delivery systems, specifically non-viral RNA delivery technologies with expertise in lipid particle formulations, genetic engineering, and targeted molecular delivery

Person of Ordinary Skill (PHOSITA) Profile

A skilled practitioner with advanced degrees in biotechnology, molecular biology, or pharmaceutical sciences, possessing knowledge of RNA synthesis, lipid particle engineering, and drug/genetic material delivery mechanisms

Obviousness Rationale

A person having ordinary skill in the art would recognize the fundamental versatility of RNA-lipid delivery technology demonstrated in the source patent and understand that its core principles could be systematically extended to novel application domains. The source patent establishes a generalizable platform for RNA encapsulation and targeted delivery using lipid particles, which provides a clear technological framework for exploring alternative use cases beyond immunization. The PTD's variations represent predictable engineering adaptations that leverage the established RNA-lipid delivery methodology.

Obvious Combinations & Variations

Source Patent Element
RNA molecules with specific encoding capabilities encapsulated in lipid particles
PTD Variation
RNA molecules encoding sensors, indicators, and functional enzymes for diverse applications
Obviousness Reasoning
A PHOSITA would recognize that RNA encoding capabilities are transferable across different functional domains, with lipid particle delivery serving as a consistent technological platform
Source Patent Element
Lipid particle composition with PEG-conjugated lipids for targeted delivery
PTD Variation
Lipid particles modified for specific tissue or environmental targeting
Obviousness Reasoning
Targeted delivery is a known technique in the art, and modifying lipid particle composition for different environments represents a predictable engineering optimization
Source Patent Element
RNA molecules with specific cap structures and 2'-methylated ribose
PTD Variation
RNA molecules synthesized for specific functional guidance or sensing purposes
Obviousness Reasoning
Molecular engineering of RNA structures for specific functional outcomes is a well-established technique within the biotechnology domain
Source Patent Element
Non-viral RNA delivery for immunological applications
PTD Variation
RNA-lipid technology applied to nutrition, agriculture, environmental monitoring
Obviousness Reasoning
Expanding technological platforms to adjacent domains represents a standard innovation strategy in biotechnology, with predictable engineering approaches
Source Patent Element
Lipid particle composition for molecular delivery
PTD Variation
Lipid particles enhanced for specific detection or environmental interaction
Obviousness Reasoning
Modifying delivery vehicles for enhanced performance is a routine optimization in drug and genetic material delivery technologies
35 U.S.C. § 103 Summary: Based on the teachings of US Patent 11857681 and the published technical disclosure, a person having ordinary skill in the art would find the claimed variations obvious, as they represent predictable extensions of established RNA-lipid delivery technologies. The disclosed innovations constitute routine engineering adaptations that would be apparent to a skilled practitioner, thereby rendering potential patent claims obvious and anticipatable by the prior art.

Original Patent Information

Patent NumberUS 11,857,681
TitleLipid formulations with RNA encoding immunogens
Assignee(s)GlaxoSmith Kline Biologicals S.A.